In this segment, series moderator Dr. Daniel George spoke to Dr. Preston C. Sprenkle about his experience with PSMA PET scans. Dr. Sprenkle noted some challenges (of using PSMA PET), but expressed that the potential of Lutetium-based PSMA treatments is very exciting.

Daniel George:

Absolutely, Oliver, they’re great points. And I think it’s one of the things that we’re really awaiting the rollout of this drug is how that’s going to translate into practice, right? Because as we’ve seen in a lot of imaging criteria, say, RECIST criteria, it doesn’t necessarily translate into practice. And, Preston, I mean, from a urologic perspective, you guys are ordering a lot of PSMA PET scans now. I’m sure in the recurrent disease setting and whatnot, you’re seeing some variation. How does this resonate with you in terms of what your experience is with PET imaging?

Preston C. Sprenkle:

Yeah. So, I mean, we definitely are using it more. I think one of the challenges, we’re still defining how to act on things that are visible on PSMA that are small. I mean, we’re still not sure exactly how to interpret that compared to our previous standard of care imaging, like bone scan and CAT scan. We are, I think, aggressively treating patients, but I think we’re all still waiting to see how that is going to work. I mean, this is with the standard of care. The introduction of Lutetium-based PSMA treatments, the potential for that is very exciting. I think that’s where we are at this point, I mean, where we have not had the opportunity to offer this yet on a trial basis in our center, but we’re very excited to see where it goes.

Daniel George:

Absolutely. Absolutely. And it is interesting. We’re seeing this uptake early in the disease and we’re seeing it persist all the way through the natural history of this disease through hormonal therapy into castration resistance, and even into chemotherapy refractory settings. Well, I think that’s really helpful and I think something for us to think about as we look at these images and report on them. They’re not necessarily reporting on these kinds of ratios, but there’s things for us to take into consideration. Well, I can’t thank you all enough for this really interesting, I think, inspiring discussion around Lutetium-177 PSMA and the potential rollout of this in the near future and what implications we have for this year and things to look forward to in the years to come. Thank you. Thank you all for joining, and on behalf of my roundtable colleagues, thank you all for listening today.